Dr. Critchfield, brings over 20 years of senior management experience in the diagnostics business, most recently serving as President of Myriad Genetic Laboratories, Inc. until his retirement earlier this year. During his tenure he launched seven novel diagnostics products across multiple technology platforms including several novel diagnostic test services for patients with cancer. Prior to Myriad, he was responsible for innovation and medicine in the spin-out of Quest Diagnostics, Inc. from Corning Clinical Laboratories, serving as Quest's Chief Medical and Science Officer.
“Greg’s experience creating and commercializing novel diagnostic products and technologies is unsurpassed,” said Dr. David Parkinson, Chief Executive Officer of Nodality. “We are pleased to have him join our Board. His ideas, knowledge and experience will no doubt assist Nodality in utilizing Single Cell Network Profiling (SCNP) in clinical test applications to better link individual patients with appropriate therapies.”
“Nodality has pioneered an incredibly powerful technology which measures specific signaling changes at the single cell level,” said Dr. Critchfield. “Nodality’s SCNP technology has now created the possibility to classify individual patients into clinically and therapeutically meaningful disease sub-groups. Nodality’s work provides novel understanding of biologic cell signals at the core of both cancer and autoimmune diseases. This exciting technology has tremendous potential in both clinical medicine and drug development.”
Dr. Critchfield received a Bachelor’s Degree in Microbiology with a minor in Chemistry from Brigham Young University in 1976, a Medical Degree from the University of Utah in 1980, and a Master’s Degree in Biophysical Sciences at the University of Minnesota in 1985. There he also completed fellowships in Clinical Chemistry and in Health Information Sciences sponsored by the National Library of Medicine and boarded in Clinical Pathology.
Nodality develops and commercializes the next generation of personal diagnostic tests by characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells. The South San Francisco-based company applies proprietary multiparametric Single Cell Network Profiling (SCNP) technology to develop highly predictive biological characterization tests to improve patient management in cancer and autoimmune diseases, the goal of personalized medicine. These tests will permit biologically informed clinical decisions of significant clinical utility. Validation studies for tests to predict success of induction chemotherapy for acute myelogenous leukemia (AML) are underway in collaboration with clinical investigators. In addition to the development of additional clinical tests for AML, SCNP is also being used in the development of new therapeutic agents for patients with other hematologic malignancies, autoimmune diseases, and solid tumors. For more information, please visit www.nodality.com.
ABOUT SINGLE CELL NETWORK PROFILING
Single Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to characterize cell signaling networks in patients with cancer and autoimmune diseases. SCNP, by measuring functional signaling network behavior in single cells, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of cellular heterogeneity including the importance of rare cells such as drug-resistant and stem cells. As the technology has widespread application in both preclinical and clinical drug development, Nodality is also utilizing SCNP in collaboration with drug developers to decrease the time, cost, and risks of drug development.
David Parkinson, MD, CEO, 650-827-8035
Andrew Hindman, 650-827-8004
SVP Corporate Development
For Media on behalf of Nodality:
Justin Jackson, 212-213-0006
Kathy Nugent, 205-401-0260
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Oncology Research Science General Health